Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 3.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 80,059 shares of the medical technology company’s stock after selling 2,566 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Stryker were worth $28,138,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $27,000. CGC Financial Services LLC bought a new stake in shares of Stryker during the 4th quarter valued at $29,000. Strive Asset Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker in the 3rd quarter valued at $34,000. Institutional investors own 77.09% of the company’s stock.
Insider Transactions at Stryker
In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last three months. Insiders own 4.60% of the company’s stock.
Stryker Price Performance
Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on SYK. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Truist Financial reissued a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Citigroup decreased their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.
Check Out Our Latest Report on Stryker
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
- Five stocks we like better than Stryker
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
